



Bacteriophages targeting adherent invasive *Escherichia coli* strains as a promising new treatment for Crohn's disease

Matthieu Galtier, Luisa de Sordi, Adeline Sivignon, Amélie de Vallée, Christel Neut, Oumaira Rahmouni, Kristin Wannerberger, Arlette Darfeuille-Michaud, Pierre Desreumaux, Nicolas Barnich, et al.

► To cite this version:

Matthieu Galtier, Luisa de Sordi, Adeline Sivignon, Amélie de Vallée, Christel Neut, et al.. Bacteriophages targeting adherent invasive *Escherichia coli* strains as a promising new treatment for Crohn's disease. *Journal of Crohn's and Colitis*, 2017, Advance publication online (7), pp.840-847. 10.1093/ecco-jcc/jjw224 . pasteur-01538942

HAL Id: pasteur-01538942

<https://pasteur.hal.science/pasteur-01538942>

Submitted on 14 Jun 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

Bacteriophages targeting adherent invasive *Escherichia coli* strains as a promising new treatment for Crohn's disease

Matthieu Galtier,^{1,2*} Luisa De Sordi,^{1*} Adeline Sivignon,³ Amélie de Vallée,³ Damien Maura,^{1,2,4} Christel Neut,^{5,6} Oumaira Rahmouni,^{5,6} Kristin Wannerberger,⁷ Arlette Darfeuille-Michaud,³ Pierre Desreumaux,^{6,8} Nicolas Barnich,³ Laurent Debarbieux¹

Running title: Phage therapy for Crohn's disease

*: these authors contributed equally to this work

1: Institut Pasteur, Biologie Moléculaire du Gène chez les Extrémophiles, Département de Microbiologie, F-75015 Paris, France

2: Université Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, rue du Docteur Roux, F-75015 Paris, France

3: Université Clermont Auvergne, UMR 1071 Inserm/Université d'Auvergne, INRA, Unité Sous Contrat 2018, Clermont-Ferrand, France

4: Present address: Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, 02114, Massachusetts, United States of America.

5: Division de Bactériologie, Faculté des Sciences Pharmaceutiques et Biologiques, Communauté d'Universités et d'Etablissements Lille Nord de France, F-59006 Lille Cedex, France.

6: Inserm U995 - LIRIC - Lille Inflammation Research International Center, F-59000 Lille, France

7 : Ferring International Center SA, Ch. de la Vergognausaz 50, 1162 St-Prex, Suisse

25 8 : CHU Lille, Service des Maladies de l'Appareil Digestif et de la Nutrition, Hôpital Claude
26 Huriez, F-59037 Lille, France
27
28 Correspondence to
29 Laurent Debarbieux
30 Institut Pasteur, Department of Microbiology, F-75015 Paris, France
31 Phone: (33) 1 44 38 92 03 - Fax: (33) 1 45 68 88 34
32 e-mail: laurent.debarbieux@pasteur.fr
33

Abstract

Background and Aims

Adherent invasive *Escherichia coli* (AIEC) are abnormally predominant on the ileal mucosa of Crohn's disease (CD) patients. They bind to the CEACAM6 receptor expressed on the surface of epithelial cells. We aimed to assess the potential of bacteriophages, viruses infecting bacteria, to decrease the levels of AIEC bacteria associated with the intestinal mucosa.

Methods

We combined *ex vivo* and *in vivo* experiments with murine and human intestinal samples to quantify the ability of virulent bacteriophages to target the prototype AIEC strain LF82.

Results

We found that three virulent bacteriophages were able to replicate in ileal, cecal and colon sections and feces homogenates from murine gut samples colonized with the prototype AIEC strain LF82. A single day of *per os* treatment with the three bacteriophages cocktail given to LF82-colonized CEABAC10 transgenic mice, expressing the human CEACAM6 receptor for AIEC, decreased significantly the number of AIEC in feces and in the adherent flora of intestinal sections. In addition, a single dose of the cocktail reduced over a two-week period DSS-induced colitis symptoms on conventional mice colonized with the strain LF82. The cocktail targeted also LF82 bacteria in homogenates of ileal biopsies taken from CD patients.

Conclusions

These findings demonstrate that bacteriophages are a new treatment option for targeting AIEC in CD patients and represent a strong basis for a clinical trial evaluation.

Introduction

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic and relapsing, life-long diseases of the gastrointestinal tract (GIT). The precise cause of IBD is unknown, but this multifactorial disease is thought to result from the complex interplay between environmental factors and genetic susceptibility, resulting in an abnormal mucosal immune response ¹. Genetic studies of CD have uncovered new mechanisms involved in the pathogenesis of this disease, including defects of a biological process called autophagy (ATG16L1 and IRGM genes), innate mucosal defense (NOD2 gene), or endoplasmic reticulum stress (Xbp1 gene) ². The higher incidence of IBD in industrialized countries than in developing countries, in which the incidence of IBD is nevertheless increasing, clearly suggests that environmental factors make an important contribution to disease pathogenesis ³. However, no strong environmental factors other than smoking and appendectomy have yet been identified for IBD ⁴. The effects of diet have been studied in detail, but the findings of these studies have been inconsistent. However, an altered gut microbiota has long been suspected to play an important role in IBD pathogenesis ^{5,6}.

In this context, the frequent recovery of particular strains of *Escherichia coli* with adherent and invasive properties (AIEC) from the mucosa of CD patients has attracted considerable attention. These bacteria constitute a new pathovar of *E. coli* lacking the type III secretion system and other classical virulence factors typically associated with pathogenic intestinal *E. coli* ⁷. The prototype AIEC strain LF82 was isolated in 1998 from a chronic ileal lesion from a CD patient ⁸. Strain LF82 has type 1 pili that can bind to the host adhesion receptor carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), which is more strongly expressed in the ileal tissues of CD patients than in those of controls ⁹. In transgenic CEABAC10 mice with high levels of expression of human CEACAMs, LF82

efficiently binds to epithelial cells and colonizes gut mucosa in a type 1 pilus-dependent manner¹⁰.

Several therapeutic strategies targeting AIEC colonization have been proposed, to slow, or even halt the natural course of CD. Manipulation of the patient's microbiota through antibiotic treatment, fecal transplantation, nutritional interventions or the administration of pre/probiotics could be used either alone or in combination with immunotherapy, to induce the remission of active disease or as a postoperative treatment to prevent relapse. However, the results obtained to date have been disappointing¹¹. Antibiotic treatments are becoming less effective, due to the increasing prevalence of multidrug resistance among bacteria, as highlighted by the World Health Organization¹². Over the last 10 years, *E. coli* has acquired worryingly high levels of resistance to multiple antibiotics, with rapid dissemination worldwide, as exemplified by the epidemic clonal complex *E. coli* ST131-O25b:H4 and more recently by the spread of plasmids carrying resistance to colistin (MCR-1), one of the last resort antibiotics^{13,14}. Dissemination occurs mostly through the digestive tract carriage of *E. coli* strains by mammals, including humans traveling between countries^{15,16}. The human digestive tract is also an environment in which bacteria can exchange genetic material, including antibiotic resistance genes, and this has led to strong recommendations that antibiotics should not be used in a prophylactic manner¹⁷.

An evaluation of non-conventional antibacterial treatments, such as those based on bacteriophages, is therefore required to deal with this major public health issue. Bacteriophages, viruses infecting bacteria, were discovered before antibiotics and have been used for many years in some countries (Georgia, Poland, Russia), in antibacterial treatments known as phage therapy¹⁸⁻²⁰. Bacteriophages are omnipresent in the environment, including the human GIT, in which they are at least as numerous as bacteria^{21,22}. Unlike antibiotics, they are highly specific, infecting only a limited number of strains within a given bacterial

107 species, and have, therefore, a much smaller impact on the composition of the microbiota²³⁻²⁵.
108 In this study, we evaluated the potential of bacteriophages to decrease intestinal colonization
109 with AIEC bacteria, in wild-type and CEACAM6-expressing mice. Our results demonstrating
110 the high efficacy of bacteriophages in reducing intestinal colonization of AIEC strain LF82
111 strongly support their clinical evaluation in CD patients.
112

Materials and Methods

Ethics statement

BALB/cYJ mice (seven-week-old females) were supplied by Charles River Laboratories and housed in an animal facility in accordance with Institut Pasteur guidelines and European recommendations. FVB/N (Friend Virus B NIH Jackson) wild-type mice provided by Charles Rivers Laboratories, France, and FVB/N CEABAC10 heterozygous transgenic mice ²⁶ were crossed in the animal care facility of the University of Auvergne (Clermont-Ferrand, France), in specific pathogen-free conditions. Food and drinking water were provided *ad libitum*. Protocols were approved by the veterinary staff of the Institut Pasteur animal facility (approval ID 10.565), the National Ethics Committee (approval number 2012-0018) and the Auvergne CEMEA (“Comité d’Ethique en Matière d’Expérimentation Animale”) committee for ethical issue (permit CEMEAA CE16-09).

Bacterial strains and growth conditions

AIEC strain LF82 ⁸ was genetically modified to generate a streptomycin-resistant strain (LF82S), through the introduction of a point mutation into the *rpsL* gene, and then to add a kanamycin resistance gene to obtain strain LF82SK. The techniques used have been described in detail elsewhere ^{27,28}. Strains were routinely cultured in lysogeny broth (LB), or on LB agar or Drigalski agar plates, at 37°C. When required, streptomycin (100 µg/ml), kanamycin (50 µg/ml), ampicillin (50 µg/ml) or erythromycin (20 µg/ml) (Sigma, St. Louis, MO) was added.

Bacteriophage isolation, preparation and characterization

We isolated and purified several bacteriophages infecting strain LF82 from wastewater, with an enrichment technique ²⁹. Since AIEC bacteria do not belong to a specific phylogenetic group or serotype, we performed host-range determination on the *E. coli* Collection of Reference (ECOR), and selected three bacteriophages, LF82_P2, LF82_P6 and LF82_P8 showing complementary host range, and prepared large-scale solutions, as previously described (see online supplementary table S1) ^{29,30}. Bacteriophage titers were determined by spotting 4 µL drops of 10-fold serial dilutions onto LB agar plates covered with a lawn of strain LF82 or LF82SK. The three-bacteriophage cocktail contained equal numbers of each of the three bacteriophages, as indicated. These three bacteriophages are equally effective against strains LF82 and LF82SK and their genomes were sequenced with Illumina technology. For each genome, a single large contig was generated by reads assembly, and this contig was used to identify closely related bacteriophage genomes with the NCBI blastn tool (see online supplementary table S2).

***Ex-vivo* replication of individual bacteriophages in colonized gut samples**

BALB/cYJ animals were kept in the animal facility for one week before experiments. Streptomycin sulfate (5 mg/ml) was added to the drinking water for three days before LF82SK administration, to disrupt the normal resident bacterial flora in the intestinal tract. Before introducing strain LF82SK, we collected feces from the mice and plated them on Drigalski agar plates, which were then incubated at 37°C for 24 hours. No bacterial colonies were observed. Mice were force-fed strain LF82SK (1×10^8 cfu) in 200 µl of sterile 20% sucrose and 2.6% sodium bicarbonate, pH 8. At the same time, the drinking water was replaced with an aqueous 0.5 mg/ml streptomycin sulfate solution. Three days later, intestinal sections from two mice were collected in aseptic conditions from LF82SK-colonized mice,

weighed (0.2 to 1 g/sample) and homogenized in 5 ml of PBS and pooled (Ultra Turrax T25, S25N-8G, IKA). Each bacteriophage (1×10^6 pfu) was added to homogenates (200 μ l), which were then incubated for 5 h at 37°C. We then spotted 10-fold serial dilutions of samples onto LB agar plates covered with a lawn of strain LF82SK for the counting of bacteriophages.

Bacteriophage treatment in CEABAC10 mice

We assessed the colonization of the gut of CEABAC10 mice with LF82, using modified version of the method described by Carvalho *et al.*¹⁰. Briefly, 8- to 10-week-old FVB/N CEABAC10 transgenic mice were given dextran sulfate sodium (DSS, molecular mass = 36,000-50,000 daltons, MP Biomedicals) at a concentration of 0.25% in drinking water (previously shown to favor gut colonization of strain LF82¹⁰), beginning three days before administration of the LF82 strain. Mice received a single dose of 5 mg of streptomycin (Euromedex) orally 24 h before oral challenge with 1×10^9 LF82 bacteria (day 0 of the experiment). On the next day, mice received PBS or the cocktail of three bacteriophages (3×10^7 pfu per mouse twice on the same day, 7 hours apart, in 200 μ l of sterile 20% sucrose and 2.6% sodium bicarbonate, pH 8) by oral gavage. Fresh fecal samples were collected to assess the degree of colonization with strain LF82. One or four days after phage administration, the mice were euthanized by cervical dislocation under isoflurane anesthesia, for assessment of the numbers of LF82 bacteria associated with colonic or ileal tissues by direct and indirect methods, and for the determination of bacteriophage levels by the spotting of 10-fold serial dilutions onto LB agar plates covered with a lawn of strain LF82. Assessment of neutrophil influx was performed on 0.5 cm-sample of proximal colon tissues (50 mg/mL), thoroughly washed in PBS and homogenized in 0.5% hexadecyltrimethylammonium bromide (Sigma) 50 mM in PBS, (pH 6.0), freeze-thawed 3 times, sonicated, and centrifuged. Myeloperoxidase

(MPO) was assayed in the supernatant by adding 1 mg/mL of dianisidine dihydrochloride (Sigma) and $5 \times 10^{-4}\%$ H_2O_2 , and the change in optical density measured at 450 nm. Human neutrophil MPO (Sigma) was used as standard. One unit of MPO activity was defined as the amount that degraded 1.0 mmole of peroxide per minute at 25°C.

Bacteriophage treatment of DSS-induced colitis in wild-type mice

BALB/cYJ animals were treated as described above for the *ex-vivo* experiments, including LF82SK gavage (1×10^8 cfu in 200 μL). The concentration of streptomycin was then decreased to 0.5 mg/ml during the entire experiment, with renewal once per week. Three days after the introduction of LF82SK, DSS (2% final concentration) was added to the drinking water. This concentration of DSS was maintained for 25 days (renewed weekly) and caused mild symptoms of colitis, as shown by the disease activity index (DAI), which takes into account weight loss, stool consistency and the presence of blood in stools (Hemocult II test (SKD SARL) (see online supplementary table S3), with no effect on mouse survival. We established this protocol from preliminary experiments in which we showed that i) decreasing streptomycin concentration had no effect on the level of gut colonization with LF82SK (assessed from feces) for up to three weeks, and ii) 1% DSS did not induce major symptoms of colitis within 10 days, whereas 3% DSS had too strong an effect, resulting in the euthanasia of the animal within three days. We also found that, in the presence of 2% DSS, mild colitis symptoms appeared seven to nine days after gavage with LF82SK. Five or seven days after the addition of 2% DSS to the drinking water, we administered the cocktail of bacteriophages (3×10^7 pfu per mouse) to the mice by oral gavage. Fecal pellets were collected at the indicated time points, for assessment of the levels of both LF82SK and bacteriophages. The mice were euthanized 25 days after the administration of the LF82SK strain, to assess

LF82SK and bacteriophage levels in organs.

Quantification of bacteria and bacteriophages in colonized mice

Freshly collected fecal samples were weighed and homogenized in PBS (0.08 g/ml final concentration), serially diluted in PBS and 4 µl of each dilution was spotted onto Drigalski agar supplemented with streptomycin and kanamycin for the quantification of strain LF82SK, or LB agar supplemented with ampicillin and erythromycin for the quantification of strain LF82. The plates were incubated for 18 h at 37°C. When necessary, ileal or colonic sections of intestines were collected in aseptic conditions, weighed, homogenized in PBS and subjected to 10-fold serial dilution and plating, as described above. When indicated, the mice received 200 µl of the cocktail of bacteriophages containing a total of 3×10^7 pfu of bacteriophages. Bacteriophages were quantified by spotting 10-fold serial dilutions onto LB agar plates covered with a lawn of strain LF82 or LF82SK. The detection limit was 5×10^2 cfu/g or pfu/g of tissue or feces.

For tissue homogenates and feces, we found, as previously reported, that direct counts of *E. coli* colonies were not accurate, because of the abundance of bacteriophages, a problem that can be overcome by using an indirect method based on qPCR³¹. Tissue homogenates (200 µl) were incubated with a mixture of DNase and RNase (0.2 mg/ml and 0.6 mg/ml final concentration respectively, Sigma) for 30 minutes at 37°C, to eliminate nucleic acids from lysed cells. They were then inactivated by heating at 95°C for 10 minutes. Bacterial DNA was extracted with a Maxwell Tissue DNA kit and a Maxwell robot (Promega, USA). InstaGene matrix (Biorad) (1/10 final volume) was added to the samples to clean up the DNA before qPCR amplification. Amplification and detection were performed in 96-well plates (Abgene), with iQ Eva Green Supermix (Biorad). Each amplification reaction was performed in

duplicate, in a final volume of 25 μ l, with a final concentration of 0.25 μ M for each primer and 5 μ l of extracted DNA (95°C for 10 min, followed by 45 cycles of 15 s at 95°C, 1 min at 60°C and 1.5 min at 72°C, and 80 cycles, beginning at 55°C, with a 0.5°C increase in each cycle, to collect melting curve data for analysis). *E. coli* 16S rDNA-specific primers and bacterial 16S rDNA universal primers were used in parallel in each PCR for the samples from the DSS-induced colitis model, whereas primers binding to the plasmid pMT (CCATTCATGCAGCAGCTCTTT and ATCGGACAACATTAGCGGTGT) were used for samples from the CEABAC10 mice ³².

***Ex-vivo* replication of the bacteriophage cocktail on ileal biopsies from CD patients**

Six frozen biopsies (obtained from the biological collection DC 2008 642) ³³ weighting 50 to 200 mg were homogenized in 0.5 to 2 ml of sterile PBS. An aliquot (50 μ l) of each homogenate was plated on Drigalski agar plates to evaluate the presence of endogenous viable Enterobacteria as well as bacteriophages infecting strain LF82SK, which both were found negative. Each homogenate was split into three aliquots of 100 μ l and 25 μ l of a bacterial suspension of strain LF82SK (3.5x10⁶ cfu), washed three times in sterile water to eliminate traces of growing medium, was added to two aliquots and incubated 60min at 37°C without shaking. Then, 25 μ l of the phage cocktail (1.8x10⁴ pfu) was added to half of the samples that received strain LF82SK as well as the samples that did not received it. Volumes were adjusted to 150 μ l with PBS. The same conditions were applied to strain LF82 growing in LB as control. Bacteriophages were enumerated after 5 and 24 hours of incubation at 37°C without shaking.

Statistical analysis

255 Data are expressed as means and SEM, and Mann–Whitney tests were carried out with Prism
256 6 software (Graphpad software, La Jolla, USA).

257

Results

Bacteriophages infect AIEC *in vitro* and *ex vivo* in colonized sections of mouse gut

Bacteriophages were isolated from wastewater and characterized *in vitro* (methods; see online supplementary table S1). We selected three bacteriophages (LF82_P2, LF82_P6 and LF82_P8) that infected both AIEC strains LF82 and LF82SK (an antibiotic-resistant derivative of strain LF82) and sequenced them. Their sequences showed that they are different to each other and revealed their similarity to previously described virulent bacteriophages (see online supplementary table S2). The ability of each bacteriophage to replicate in an intestinal environment was studied *ex vivo* in gut homogenates from the small and large intestines collected from LF82SK-colonized mice (figure 1) ³¹. Bacteriophages LF82_P2 and LF82_P6 displayed similar profiles, with higher levels of amplification from ileal and colonic sections than from the cecum and feces, whereas amplification levels for LF82_P8 were high and similar for all gut sections.

Bacteriophages reduce the colonization of the gut by AIEC strain LF82 in transgenic mice expressing the human CEACAM6 glycoprotein

We then investigated the ability of a cocktail of these three bacteriophages (equal amounts of each bacteriophage) to infect adherent LF82 bacteria, in the CEABAC10 transgenic mouse model, which expresses the human CEACAM6 receptor for AIEC bacteria ¹⁰. LF82-colonized mice received two 3×10^7 pfu doses of the cocktail on the same day, administered *per os* (bacteriophage group), or two doses of PBS (control group) (figure 2A). Twenty-four hours post-treatment, the concentration of strain LF82 in feces had fallen significantly, by two orders of magnitude, in the bacteriophage group. It remained significantly lower than that in the control group four days after treatment, without the administration of additional bacteriophages (figure 2B). Concomitantly we observed that the number of bacteriophages in

feces in the bacteriophage group decreases accordingly to the concentration of strain LF82, while in the group of non-colonized mice it had fallen below the detection threshold within 24 hours (figure 2C). These variations did not affect the weight of animals neither MPO levels in ileum and colon sections collected at day 5 (see online supplementary figure S1).

We also analyzed the adherent *E. coli* bacteria from ileal and colonic gut sections from both the bacteriophage and control groups, with a semi-quantitative real-time PCR method for bacterial quantification (the abundance of bacteriophages in samples has been shown to affect the accuracy of direct bacterial counts³¹). Twenty-four hours post-treatment, the levels of the adherent strain LF82 (figure 3A) were significantly lower in all the gut sections of the bacteriophage group than in those of the control group. Four days post-treatment, the differences between the two groups remained significant, other than for ileal sections (figure 3B). Thus, by direct and indirect methods, we showed that the administration of a bacteriophage cocktail on one day progressively reduced the level of LF82 colonization of the entire GIT over the following five days, despite the expression of the CEACAM6 receptor for AIEC.

Bacteriophages reduce colitis symptoms in conventional mice colonized with AIEC strain LF82SK

We moved one step closer to clinical settings, by investigating the relationship between the ability of bacteriophages to decrease colonization by AIEC and the control of intestinal colitis symptoms induced by DSS in conventional mice, by determining DAI score (methods). Three groups of mice colonized with strain LF82SK received three independent treatments (figure 4A). As a preliminary study showed that DAI score increased between seven and nine days after the administration of the LF82SK strain (methods), we investigated whether the

administration of a single dose of the bacteriophage cocktail (3×10^7 pfu) either before (on day 8; preventive treatment) or after (on day 10; curative treatment) LF82SK administration could affect colitis symptoms and LF82SK colonization levels. In the group receiving the preventive treatment, DAI score on day 10 was lower than that in the other two groups. It subsequently returned to background levels, and remained at this level for the next 15 days (figure 4B). In the group receiving the curative treatment on day 10, DAI had decreased four days post-treatment, but to a lesser extent than in the control group, and it remained low for the next 11 days (figure 4B). Mean fecal levels of strain LF82SK from day 7 to day 25 remained stable in the control group (from $3.6 \times 10^9 \pm 2.2 \times 10^9$ to $3.6 \times 10^8 \pm 3.34 \times 10^8$ cfu/g) but decreased by 6.000 (from $4.8 \times 10^9 \pm 1.6 \times 10^9$ to $7.7 \times 10^5 \pm 1.1 \times 10^6$ cfu/g) and 43.000 ($4.0 \times 10^9 \pm 1.4 \times 10^9$ to $9.3 \times 10^4 \pm 1.1 \times 10^5$ cfu/g) times respectively in the preventive and curative groups. Furthermore, these results were confirmed using molecular quantification of ileal and colonic sections collected on day 25 (figure 4 C,D). A single bacteriophage application therefore successfully decreased colitis symptoms and mediated the long-term decolonization of the GIT with AIEC.

Bacteriophages actively replicate on ileal biopsies from CD patients

In order to provide an evaluation of the potential of this cocktail to target AIEC strains in patients we measured its replication in six CD patients ileal biopsies spiked with strain LF82SK. Active replication of the cocktail was measured after 5 hours from bacteriophage administration (mean n-fold replication $9.43 \times 10^3 \pm 2.07 \times 10^3$) and after 24 hours (mean n-fold replication $3.22 \times 10^4 \pm 6.31 \times 10^3$) confirming the killing potential of the cocktail in such environment. Values were similar to those obtained with individual bacteriophages from ileal samples of LF82SK-colonized mice.

Discussion

Dysbiosis of the gut microbiota is now recognized as a hallmark of IBD. It leads to the overgrowth of enterobacteria, including *E. coli* strains from the AIEC group, which are particularly predominant³⁴. Antibiotic treatments have been proposed but expose CD patients to the risk of adverse events, such as exacerbation of dysbiosis, with detrimental effects, such as promotion of the growth of pathogenic strains or an increase in inflammation. Antibiotic-resistant bacteria may also be selected, decreasing the chances of a successful treatment outcome. Furthermore, the long-term antibiotic treatments with ciprofloxacin and metronidazole frequently used to treat CD are associated with a high risk of adverse effects resulting in treatment intolerance. Phage therapy is not only a specific way to target pathogens with a lower impact on microbiota than antibiotics, it can also provide a solution to the problem of antibiotic-resistant strains^{24,25,35,36}. In this study, we investigated the activity of a cocktail of three bacteriophages targeting AIEC strain LF82. The choice of these bacteriophages was guided to obtain the largest host range towards the ECOR collection, which embraces the genetic diversity of *E. coli* genus, as AIEC strains do not belong to a particular genotype or serotype. An complementary strategy could consist on using a collection of characterized AIEC strains to implement this initial cocktail towards CD patients strains.

We showed *ex vivo* that each bacteriophage was able to replicate in the GIT. As in similar experiments performed previously with six bacteriophages infecting two different strains of *E. coli*, we found that each of the three LF82 bacteriophages replicated in gut sections^{25,31}. These three LF82-bacteriophages belong to the *Myoviridae* family of viruses, whereas the bacteriophages previously reported to have a lower performance belong to the *Podoviridae* and *Siphoviridae* families. However, we found that all nine bacteriophages tested *ex vivo* to

date replicated strongly in the ileal section of the GIT, suggesting that this compartment does not restrict bacterial permissivity to bacteriophage infection as also supported by the high level of bacteriophage cocktail replication in ileal biopsies of CD patients. On the other hand, in other mouse gut sections, bacteriophage replication was highly variable. Therefore, the biogeography of the GIT probably affects bacteriophage replication, possibly due to differences in bacterial physiology between different GIT sections, which in addition display different mucus layers that are associated with specific microbiota³⁷⁻⁴⁰. Also, recent evidences showed that some bacteriophages bind mucus which could affect their persistence in the GIT^{41,42}.

Using CEABAC10 mice, we showed that the cocktail of bacteriophages strongly decreased intestinal colonization by strain LF82, suggesting that bacteriophages were able to reach the epithelial surface bearing the CEACAM6 receptor of strain LF82. This strong decrease was observed with both CEABAC10 and conventional mice in the absence and presence of antibiotic pressure, respectively. These reduced colonization levels, obtained with a single application of the cocktail, were highly significant (relative to the control groups) and they persisted for at least two weeks, corresponding to the highest efficacy ever reported in experimental models of intestinal colonization, perhaps because we used a cocktail of three *Myoviridae*^{25,31,43,44}. Thus, one of the key characteristics and advantages of bacteriophages over antibiotics, their ability to self-amplify and increase their own concentrations locally, translated directly into a decrease in the concentration of the target bacteria in the GIT. Self-limitation was also observed, as the number of bacteriophages decreased over time, with decreasing levels of their target. In addition, we found that the decrease in AIEC levels mediated by bacteriophage treatment was accompanied by a decrease in colitis symptoms, a promising result for possible future clinical applications.

383

384 The safety of bacteriophages targeting intestinal pathogens is well documented for adults and
385 infants, based on data for a clinical trial on diarrheal diseases, in which no adverse events
386 were reported ^{23,24,45}. This is not surprising, as bacteriophages are the most abundant viruses
387 present in the human GIT, being part of our natural microbiota, and are far more abundant
388 than viruses infecting eukaryotic cells ^{46,47}. Recent virome studies on samples from IBD
389 patients showed that the microbiota of these patients displayed an altered bacteriophage
390 composition, raising questions about the possible role of these viruses in the disease ⁴⁸. Most
391 of the bacteriophages detected were temperate (as opposed to virulent), suggesting a possible
392 role in dynamic interactions between bacteria, possibly leading to genetic exchanges ⁴⁹. The
393 bacteriophages recommended for therapeutic applications, such as those reported here, are
394 virulent, and our experimental data support their use for targeting AIEC strains as part of a
395 gentle approach to reestablishing eubiosis in CD patients, possibly extending the intervals
396 between relapses.

397

398

399

400

401 **Acknowledgments**

402 We thank Alexander Sulakvelidze (Intralytix, Baltimore, USA) for bacteriophage sequencing
403 and Laurent Dubuquoy (LIRIC - UMR995, Faculté de Médecine, Lille, France) for providing
404 human ileal biopsies. This work was partly supported by DigestScience Foundation (Lille,
405 France) and Ferring Pharmaceuticals (St Prex, Switzerland), the *Ministère de la Recherche et*
406 *de la Technologie*, Inserm (UMR1071) and INRA (USC-2018). D. Maura and M. Galtier
407 were supported by PhD fellowships from the *Ministère de l'Enseignement Supérieur et de la*
408 *Recherche* (ED N°516 B3MI / ED N°157 BioSPC Paris Diderot Université).

409

410 The funders had no role in study design, data collection and interpretation, or the decision to
411 submit the work for publication.

412

413 **Conflict of interest statement**

414 Pierre Desreumaux and Laurent Debarbieux have received consulting fees and research grants
415 from Ferring SA.

416 Kristin Wannerberger is an employee of Ferring SA.

417

418

References

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 2007;**448**:427-34.
2. Liu JZ, van Sommeren S, Huang H, *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet* 2015;**47**:979-86.
3. Legaki E, Gazouli M. Influence of environmental factors in the development of inflammatory bowel diseases. *World J Gastrointest Pharmacol Ther* 2016;**7**:112-25.
4. Carbonnel F, Jantchou P, Monnet E, Cosnes J. Environmental risk factors in crohn's disease and ulcerative colitis: An update. *Gastroenterol Clin Biol* 2009;**33 Suppl 3**:S145-57.
5. Frank DN, St Amand AL, Feldman RA, *et al.* Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* 2007;**104**:13780-5.
6. Kaur N, Chen CC, Luther J, Kao JY. Intestinal dysbiosis in inflammatory bowel disease. *Gut Microbes* 2011;**2**:211-6.
7. Miquel S, Peyretailade E, Claret L, *et al.* Complete genome sequence of crohn's disease-associated adherent-invasive e. Coli strain If82. *PLoS One* 2010;**5**.
8. Darfeuille-Michaud A, Neut C, Barnich N, *et al.* Presence of adherent escherichia coli strains in ileal mucosa of patients with crohn's disease. *Gastroenterology* 1998;**115**:1405-13.
9. Barnich N, Carvalho FA, Glasser AL, *et al.* Ceacam6 acts as a receptor for adherent-invasive e. Coli, supporting ileal mucosa colonization in crohn disease. *J Clin Invest* 2007;**117**:1566-74.
10. Carvalho FA, Barnich N, Sivignon A, *et al.* Crohn's disease adherent-invasive escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human ceacam. *J Exp Med* 2009;**206**:2179-89.
11. Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in ibd: Current results and future approaches. *Curr Treat Options Gastroenterol* 2015;**13**:105-20.

- 445 12. Antimicrobial resistance: Global report on surveillance 2014.
446 <http://www.who.int/drugresistance/documents/surveillancereport/en/>, World Health
447 Organization.
- 448 13. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli st131, an intriguing clonal
449 group. *Clin Microbiol Rev* 2014;**27**:543-74.
- 450 14. Liu YY, Wang Y, Walsh TR, *et al.* Emergence of plasmid-mediated colistin resistance
451 mechanism mcr-1 in animals and human beings in china: A microbiological and molecular
452 biological study. *Lancet Infect Dis* 2016;**16**:161-8.
- 453 15. Lubbert C, Straube L, Stein C, *et al.* Colonization with extended-spectrum beta-lactamase-
454 producing and carbapenemase-producing enterobacteriaceae in international travelers
455 returning to germany. *Int J Med Microbiol* 2015;**305**:148-56.
- 456 16. Bernasconi OJ, Kuenzli E, Pires J, *et al.* Travelers can import colistin-resistant
457 enterobacteriaceae, including those possessing the plasmid-mediated mcr-1 gene.
458 *Antimicrob Agents Chemother* 2016;**60**:5080-4.
- 459 17. Broaders E, Gahan CG, Marchesi JR. Mobile genetic elements of the human gastrointestinal
460 tract: Potential for spread of antibiotic resistance genes. *Gut Microbes* 2013;**4**:271-80.
- 461 18. Sulakvelidze A, Alavidze Z, Morris JG, Jr. Bacteriophage therapy. *Antimicrob Agents*
462 *Chemother* 2001;**45**:649-59.
- 463 19. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections.
464 *Bacteriophage* 2011;**1**:66-85.
- 465 20. Knoll BM, Mylonakis E. Antibacterial bioagents based on principles of bacteriophage biology:
466 An overview. *Clin Infect Dis* 2014;**58**:528-34.
- 467 21. Reyes A, Haynes M, Hanson N, *et al.* Viruses in the faecal microbiota of monozygotic twins
468 and their mothers. *Nature* 2010;**466**:334-8.
- 469 22. Hoyles L, McCartney AL, Neve H, *et al.* Characterization of virus-like particles associated with
470 the human faecal and caecal microbiota. *Res Microbiol* 2014;**165**:803-12.

- 471 23. McCallin S, Alam Sarker S, Barretto C, *et al.* Safety analysis of a russian phage cocktail: From
472 metagenomic analysis to oral application in healthy human subjects. *Virology* 2013;**443**:187-
473 96.
- 474 24. Sarker SA, Sultana S, Reuteler G, *et al.* Oral phage therapy of acute bacterial diarrhea with
475 two coliphage preparations: A randomized trial in children from bangladesh. *EBioMedicine*
476 2016;**4**:124-37.
- 477 25. Galtier M, De Sordi L, Maura D, *et al.* Bacteriophages to reduce gut carriage of antibiotic
478 resistant uropathogens with low impact on microbiota composition. *Environ Microbiol*
479 2016;**18**:2237-45.
- 480 26. Chan CH, Stanners CP. Novel mouse model for carcinoembryonic antigen-based therapy. *Mol*
481 *Ther* 2004;**9**:775-85.
- 482 27. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in escherichia coli k-
483 12 using pcr products. *Proc Natl Acad Sci U S A* 2000;**97**:6640-5.
- 484 28. Chaverocche MK, Ghigo JM, d'Enfert C. A rapid method for efficient gene replacement in the
485 filamentous fungus aspergillus nidulans. *Nucleic Acids Res* 2000;**28**:E97.
- 486 29. Debarbieux L, Leduc D, Maura D, *et al.* Bacteriophages can treat and prevent pseudomonas
487 aeruginosa lung infections. *J Infect Dis* 2010;**201**:1096-104.
- 488 30. Ochman H, Selander RK. Standard reference strains of escherichia coli from natural
489 populations. *J Bacteriol* 1984;**157**:690-3.
- 490 31. Maura D, Galtier M, Le Bouguenec C, Debarbieux L. Virulent bacteriophages can target
491 o104:H4 enteroaggregative escherichia coli in the mouse intestine. *Antimicrob Agents*
492 *Chemother* 2012;**56**:6235-42.
- 493 32. Furet JP, Firmesse O, Gourmelon M, *et al.* Comparative assessment of human and farm
494 animal faecal microbiota using real-time quantitative pcr. *FEMS Microbiol Ecol* 2009;**68**:351-
495 62.

- 496 33. Bouguen G, Langlois A, Djouina M, *et al.* Intestinal steroidogenesis controls ppargamma
497 expression in the colon and is impaired during ulcerative colitis. *Gut* 2015;**64**:901-10.
- 498 34. Gevers D, Kugathasan S, Denson LA, *et al.* The treatment-naïve microbiome in new-onset
499 crohn's disease. *Cell Host Microbe* 2014;**15**:382-92.
- 500 35. Sarker SA, Sultana S, Reuteler G, *et al.* Oral phage therapy of acute bacterial diarrhea with
501 two coliphage preparations: A randomized trial in children from bangladesh. *EBioMedicine*.
- 502 36. Dufour N, Clermont O, La Combe B, *et al.* Bacteriophage Im33_p1, a fast-acting weapon
503 against the pandemic st131-o25b:H4 escherichia coli clonal complex. *J Antimicrob Chemother*
504 2016.
- 505 37. Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, *et al.* The composition of the gut microbiota
506 shapes the colon mucus barrier. *EMBO Rep* 2015;**16**:164-77.
- 507 38. Johansson ME, Sjovall H, Hansson GC. The gastrointestinal mucus system in health and
508 disease. *Nat Rev Gastroenterol Hepatol* 2013;**10**:352-61.
- 509 39. Nielsen AT, Dolganov NA, Rasmussen T, *et al.* A bistable switch and anatomical site control
510 vibrio cholerae virulence gene expression in the intestine. *PLoS Pathog* 2010;**6**:e1001102.
- 511 40. Li H, Limenitakis JP, Fuhrer T, *et al.* The outer mucus layer hosts a distinct intestinal microbial
512 niche. *Nat Commun* 2015;**6**:8292.
- 513 41. Barr JJ, Auro R, Furlan M, *et al.* Bacteriophage adhering to mucus provide a non-host-derived
514 immunity. *Proc Natl Acad Sci U S A* 2013;**110**:10771-6.
- 515 42. Barr JJ, Auro R, Sam-Soon N, *et al.* Subdiffusive motion of bacteriophage in mucosal surfaces
516 increases the frequency of bacterial encounters. *Proc Natl Acad Sci U S A* 2015;**112**:13675-80.
- 517 43. Weiss M, Denou E, Bruttin A, *et al.* In vivo replication of t4 and t7 bacteriophages in germ-
518 free mice colonized with escherichia coli. *Virology* 2009;**393**:16-23.
- 519 44. Chibani-Chennoufi S, Sidoti J, Bruttin A, *et al.* In vitro and in vivo bacteriolytic activities of
520 escherichia coli phages: Implications for phage therapy. *Antimicrob Agents Chemother*
521 2004;**48**:2558-69.

- 522 45. Sarker SA, McCallin S, Barretto C, *et al.* Oral t4-like phage cocktail application to healthy adult
523 volunteers from bangladesh. *Virology* 2012;**434**:222-32.
- 524 46. Lim ES, Zhou Y, Zhao G, *et al.* Early life dynamics of the human gut virome and bacterial
525 microbiome in infants. *Nat Med* 2015;**21**:1228-34.
- 526 47. Debarbieux L. Bacterial sensing of bacteriophages in communities: The search for the rosetta
527 stone. *Curr Opin Microbiol* 2014;**20**:125-30.
- 528 48. Norman JM, Handley SA, Baldrige MT, *et al.* Disease-specific alterations in the enteric
529 virome in inflammatory bowel disease. *Cell* 2015;**160**:447-60.
- 530 49. De Paepe M, Leclerc M, Tinsley CR, Petit MA. Bacteriophages: An underestimated role in
531 human and animal health? *Front Cell Infect Microbiol* 2014;**4**:39.

532

533




Figure 1 The three bacteriophages replicate *ex vivo* in all gut sections

Ileal (il.), cecal (ce.), colonic (co.) and fecal (fe.) gut sections collected from two LF82SK-colonized mice over a three-day period, and LB medium containing exponentially growing LF82SK (Ct), were mixed with each individual bacteriophages at an MOI of 0.01 in three replicates. Number of plaques formed on LF82SK lawns from the corresponding supernatants, following 5 hours of incubation at 37°C, plotted as n-fold multiplication relative to the initial number of bacteriophages added.




Figure 2 Levels of the AIEC strain LF82 in feces are reduced by bacteriophage treatment


(A) Experimental setting, indicating the administration of streptomycin (str, 5 mg per mouse continuously exposed to 0.25% DSS) 24 hours before oral gavage with the AIEC strain LF82 (1×10^9 bacteria per mouse) followed by administration of either PBS or a cocktail of the three bacteriophages (3×10^7 pfu per mouse, administered twice on the same day, 7 hours apart).

(B) Levels of the AIEC strain LF82 (CFU) recovered from the feces of LF82-colonized mice receiving either PBS (black; $n=13$ to 30) or the bacteriophage cocktail (white; $n=12$ to 23), at various times post-infection.

(C) Levels of the bacteriophage cocktail (PFU) in the feces of LF82-free (gray; $n=24$ to 12) and LF82-colonized (white; $n=12$ to 23) mice.

** = $p < 0.01$ and **** = $p < 0.0001$

560



561

562 **Figure 3 The bacteriophage cocktail strongly reduces the colonization of the entire gut**
 563 **with the AIEC strain LF82**

564 Analysis of the LF82 content of intestinal sections collected on days 2 and 5 from mice (n=6
 565 to 14) that received either PBS (black) or the cocktail of three bacteriophages (white; 3×10^7
 566 pfu per mouse) at the indicated time (same experimental setting that in figure 2A), assessed
 567 by qPCR with primers binding to the pMT plasmid. ns = not significant; ** = $p < 0.01$; *** =
 568 $p < 0.005$

569





Figure 4 Preventive and curative single administrations of bacteriophages reduce both DSS-induced colitis symptoms and AIEC colonization

(A) Schematic diagram of the experiment with three groups of mice ($n=5$) receiving either PBS or a single dose of the cocktail on day 8 (3×10^7 pfu) or a single dose of the cocktail (3×10^7 pfu) on day 10.

(B) The disease activity index was recorded at the indicated time points and plotted for each group of mice (control, preventive and curative).

(C, D) On day 25, ileal (C) and colonic (D) gut sections were analyzed by qPCR to quantify *E. coli* relative to the total number of bacteria for each mouse. * = $p < 0.05$; ** = $p < 0.01$.

582 Supplementary data



583

584 **Figure S1** Evolution of body weight and level of MPO of CEABAC10 mice colonized with

585 strain LF82 and receiving either PBS or a the cocktail of bacteriophages

586 (A) Experimental setting, indicating the administration of streptomycin (str, 5 mg per mouse

587 continuously exposed to 0.25% DSS) 24 hours before oral gavage with the AIEC strain LF82

588 (1×10^9 bacteria per mouse) followed by administration of either PBS or a cocktail of the

589 three bacteriophages (3×10^7 pfu per mouse, administered twice on the same day, 7 hours

590 apart).

591 (B) Evolution of body weight of the two groups of CEABAC10 mice colonized with strain

592 LF82 and receiving either PBS (n=13) or the cocktail of bacteriophages (n=12). For clarity

593 SEM are not indicated but were all below 4%.

594 (C) MPO levels measured at day 5 from ileum and colon sections taken from CEABAC10

595 mice receiving either PBS (n=13) or the cocktail (n=12)

Table S1 Host range of the three LF82-specific bacteriophages on the *Escherichia coli* Collection of Reference (ECOR)

LF82_	P2	P6	P8
LF82SK	+++*	+++	+++
ECOR 1	+++	+++	-
ECOR 9	-	-	+++
ECOR 16	+++	+++	+++
ECOR 17	-	-	+++
ECOR 24	++	-	-
ECOR 25	-	-	+++
ECOR 26	-	-	+++
ECOR 27	-	-	++
ECOR 28	-	-	+++
ECOR 29	-	-	+++
ECOR 30	-	-	+++
ECOR 34	-	-	+++
ECOR 35	-	-	+++
ECOR 36	-	-	+++
ECOR 39	++	-	+++
ECOR 42	+++	+++	-
ECOR 43	-	-	+++
ECOR 44	-	-	+++
ECOR 46	-	-	+++
ECOR 48	+++	-	-
ECOR 55	-	-	++
ECOR 56	+++	-	-
ECOR 63	+++	+++	+++
ECOR 70	-	-	+++
ECOR 71	+++	+++	-

*, +++, $0.1 > \text{EOP} > 1$; ++, $0.001 > \text{EOP} > 0.1$; + $0.00001 > \text{EOP} > 0.001$; - $\text{EOP} = 0$. The ECOR strains not indicated in this table (47 in total) were not infected by any of the three bacteriophages.

Table S2 Bacteriophages closely related to LF82_P2, LF82_P6 and LF82_P8 (genomes with more than 90% query coverage in Megablast nucleotide analysis, ranked in decreasing order of query cover, are indicated).

Homologs to LF82_P2						
Description	Max score	Total score	Query cover	E value	Identity	Accession
Escherichia phage vB_EcoM-VpaE1	37362	1.304e+05	93%	0.0	97%	KM657822.1
Escherichia phage JH2	26005	1.257e+05	93%	0.0	97%	KF055347.1
Escherichia phage vB_EcoM_AYO145A	37742	1.325e+05	92%	0.0	96%	KR014248.1
Enterobacteriophage UAB_Phi87	36509	1.312e+05	92%	0.0	97%	JN225449.1
Escherichia coli O157 typing phage 12	34743	1.319e+05	92%	0.0	95%	KP869110.1
Escherichia coli O157 typing phage 11	34743	1.319e+05	92%	0.0	95%	KP869109.1
Escherichia coli O157 typing phage 8	34743	1.316e+05	92%	0.0	95%	KP869106.1
Enterobacteria phage WV8	34736	1.316e+05	92%	0.0	95%	EU877232.1
Escherichia coli O157 typing phage 15	34322	1.321e+05	92%	0.0	95%	KP869113.1
Escherichia coli O157 typing phage 1	20473	1.316e+05	92%	0.0	97%	KP869100.1
Bacteriophage Felix 01	36784	1.268e+05	90%	0.0	96%	AF320576.1
Salmonella phage Mushroom	36714	1.291e+05	90%	0.0	96%	KP143762.1
Escherichia phage HY02	35336	1.277e+05	90%	0.0	94%	KM092515.1
Homologs to LF82_P6						
Description	Max score	Total score	Query cover	E value	Identity	Accession
Escherichia phage vB_EcoM-VpaE1	37877	1.330e+05	94%	0.0	97%	KM657822.1
Escherichia coli O157 typing phage 12	34553	1.354e+05	94%	0.0	94%	KP869110.1
Escherichia coli O157 typing phage 11	34553	1.358e+05	94%	0.0	94%	KP869109.1
Escherichia coli O157 typing phage 8	34553	1.353e+05	94%	0.0	94%	KP869106.1
Enterobacteria phage WV8	34551	1.353e+05	94%	0.0	94%	EU877232.1
Escherichia coli O157 typing phage 15	34188	1.359e+05	94%	0.0	94%	KP869113.1
Escherichia coli O157 typing phage 1	20255	1.341e+05	94%	0.0	97%	KP869100.1
Escherichia phage vB_EcoM_AYO145A	38753	1.329e+05	93%	0.0	96%	KR014248.1
Escherichia phage HY02	36963	1.291e+05	93%	0.0	94%	KM092515.1
Enterobacteriophage UAB_Phi87	36954	1.320e+05	93%	0.0	97%	JN225449.1
Salmonella phage Mushroom	36937	1.284e+05	92%	0.0	97%	KP143762.1
Escherichia phage JH2	27069	1.248e+05	92%	0.0	97%	KF055347.1
Bacteriophage Felix 01	36996	1.256e+05	91%	0.0	97%	AF320576.1
Salmonella phage HB-2014	25418	1.238e+05	91%	0.0	97%	KP010413.1
Homologs to LF82_P8						
Description	Max score	Total score	Query cover	E value	Identity	Accession
Escherichia phage vB_EcoM_JS09	69335	2.754e+05	97%	0.0	97%	KF582788.1
Escherichia coli O157 typing phage 3	40680	2.760e+05	97%	0.0	97%	KP869101.1
Enterobacteria phage HX01	34452	2.661e+05	95%	0.0	97%	JX536493.1
Enterobacteria phage RB69	36212	2.406e+05	93%	0.0	97%	AY303349.1
Escherichia phage vB_EcoM_PhAPEC2	32398	2.453e+05	93%	0.0	97%	KF562341.1
Escherichia coli O157 typing phage 13	31852	2.647e+05	93%	0.0	98%	KP869111.1
Shigella phage Shf125875	30204	2.442e+05	93%	0.0	96%	KM407600.1
Escherichia coli O157 typing phage 6	40686	2.638e+05	92%	0.0	97%	KP869104.1
Escherichia phage EC6	25281	1.224e+05	90%	0.0	97%	JX560968.1

608 **Table S3** Disease activity index

	Score	Criteria
Body weight loss	0	no loss
	1	1 to 5%
	2	5 to 10 %
	3	10 to 20%
	4	>20%
Stool consistency	0	normal feces
	1	loose stools
	2	watery diarrhea
	3	slimy diarrhea, little diarrhea
	4	severe watery diarrhea with blood
Blood in stools	0	no blood
	1	weakly positive Hemoccult test
	2	moderately positive Hemoccult test
	3	highly positive Hemoccult test
	4	visible blood

609

610